BMEA logo

Biomea Fusion, Inc. Common Stock


BMEA: Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.


Show BMEA Financials

Consumer Interest
SEC Filings

Recent trades of BMEA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BMEA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of BMEA in WallStreetBets Daily Discussion


Recent insights relating to BMEA

CNBC Recommendations

Recent picks made for BMEA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BMEA

Corporate Flights

Flights by private jets registered to BMEA